KDM1A and acute myeloid leukemia: Finally, we investigated combinations of the dual HDAC6/LSD1 inhibitor with cytotoxic agents that are the current standard of care in acute myeloid leukemia (AML) and discovered a significant enhancement of doxorubicin sensitivity.